Newly debuted biotech shoots for $40M IPO; Intellia touts new animal data on CRISPR/Cas9

⇨ Just 8 months after making its debut at the beginning of the year, Cambridge, MA-based Cue Biopharma has filed for a $40 million IPO. The TCR company is based on work done at Albert Einstein College of Medicine. The biotech window has opened considerably in the last few months, but a fledgling company like this could well test investors’ appetite for the unknown. According to the S-1, they’re still involved in preclinical work.

⇨ Gene editing companies arrived early on Wall Street, and now look to encourage investors with the latest animal data regarding CRISPR/Cas9. Intellia $NTLA today is touting “full 12-month data of its completed long-term mouse study, demonstrating robust and durable in vivo genome editing post single-dose, intravenous administration using its proprietary lipid nanoparticle delivery system.”

⇨ GTx $GTXI has raised $48.5 million through a private placement of stock.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->